Estriol: The Definitive Guide

What is estriol?

Estriol, often called E3, is an estrogen molecule. The regulated products covered here are vaginal medicines for estrogen-deficiency symptoms after menopause. They act mainly on local tissues and are not substitutes for a systemic hot-flash regimen. “Weaker estrogen” is an incomplete description: formulation, applied amount and repeated exposure matter more than a nickname. [1], [2], [3], [4]

Authorization differs by country. UK products include prescription estriol cream and pessaries, as well as Ovesse under a defined pharmacy-access pathway. Ireland has an authorized Ovestin cream. The FDA explicitly states that no estriol-containing drug is FDA-approved. A compounded US cream therefore is not the same regulatory product as a named authorized cream overseas. [1], [2], [3], [4], [5], [11]

This guide compares specific public labels. It does not certify all estriol products worldwide, online “natural hormone” creams or mixtures called Biest. Check the exact concentration, route and package instructions before comparing amounts. A facial cream, vaginal medicine and systemic preparation cannot be assigned one shared dosing or safety profile. [1], [2], [3], [4], [5], [8]

Typical Estriol Protocols

The initial daily period is part of each product’s full schedule. It is two weeks for Ovesse, three weeks for Imvaggis and up to four weeks for the named prescription cream and Irish Ovestin. Do not transfer the longest initial period to every product or remain on daily use indefinitely because symptoms have not completely resolved. Response-guided maintenance and reassessment are part of the instructions. [1], [2], [3], [4]

A 1 mg/g cream contains 1 mg estriol in each gram. Its marked 0.5 g applicator dose therefore supplies 0.5 mg. Imvaggis instead contains 0.03 mg, or 30 mcg, per pessary. These numbers describe medicine placed in the vagina; they are not measured absorbed doses and are not evidence that one formulation is more effective than another. Grams, milligrams and micrograms should stay attached to the product name. [1], [2], [3], [4]

With low systemic exposure under the labeled vaginal schedules, these SmPCs generally do not recommend adding progestogen solely for the local product. This does not protect someone who also uses systemic estrogen without adequate opposition, nor does it excuse unexplained bleeding. [1], [2], [3], [4]

Evidence note: rows are authorized product schedules from selected UK and Irish full SmPCs. They are not US approvals, compounded dosing instructions or recommendations for facial use.

Which symptoms can local estriol help?

Local estriol treats vaginal atrophy associated with estrogen deficiency: dryness, soreness, burning and discomfort during sex can improve. Some urinary symptoms are part of genitourinary syndrome of menopause, or GSM, but not every urinary problem is due to low estrogen. Persistent urinary pain, discharge, skin changes or bleeding may need investigation for another cause. Local estrogen is one treatment option alongside moisturizers and lubricants. [1], [2], [3], [4], [6], [7]

The goal is comfortable tissue function, not a guaranteed increase in desire, treatment of every bladder problem or improvement in systemic night sweats. If hot flashes or bone replacement are the principal issue, this local schedule is the wrong evidence base for a systemic prescription. Likewise, applying a vaginal estriol medicine to the face is a different use and cannot inherit its approved vaginal indication or trial findings. [1], [2], [3], [4]

With a breast-cancer history, especially during aromatase-inhibitor treatment, first discuss nonhormonal measures and involve the appropriate clinical team before considering vaginal estrogen. A general low-dose guideline does not override the named product’s contraindications or settle an individual cancer-care decision. [1], [2], [3], [6], [7]

How should vaginal estriol be applied?

Use the route and applicator specified on the package. The creams’ marked applicators control grams of cream; a spoon, finger-sized estimate or another brand’s applicator does not reproduce that instruction. Follow its cleaning directions. Pessaries are inserted according to their own leaflet, usually in the evening. Do not swallow a pessary or turn an intravaginal schedule into a facial-use regimen. [1], [2], [3], [4]

Missed-dose advice also differs. The UK prescription cream says to skip a missed application when more than 12 hours overdue and never administer two doses on the same day. Imvaggis distinguishes missed doses during its initial daily course from maintenance doses. Keep the product leaflet rather than relying on one universal catch-up rule. [2], [3]

Atrophic tissue can be tender. Persistent burning after application may reflect local irritation, an excipient reaction, infection or another problem. Applying extra medicine is not a diagnostic test for the cause. Tell the clinician whether pain began before treatment, occurs only during application or continues afterward. [1], [2], [3], [4], [6]

Does local treatment mean no absorption?

No. Estriol binds estrogen receptors and supports maturation of vaginal tissue. Some of a vaginal dose reaches the circulation. The Imvaggis SmPC describes lower peak estriol exposure after repeated daily treatment than after the initial dose; this is a product-specific pharmacokinetic finding, not proof that every estriol preparation has zero systemic effect. [3]

The distinction is between low local exposure under a defined regimen and a larger or systemic regimen. “Natural,” “short acting” and “weak” cannot replace that assessment. The legacy assertion that estriol never binds any SHBG was also too absolute: the Imvaggis label describes a small bound fraction. Binding details do not supply a personal safety guarantee. [1], [2], [3], [4]

How strong is the human evidence?

Imvaggis has a randomized double-blind placebo-controlled trial described in its SmPC. It enrolled 438 postmenopausal women and found improvements in vaginal tissue measures and the most bothersome symptom after 12 weeks. Those are direct local-treatment outcomes. They do not establish prevention of breast cancer, cardiovascular disease or dementia, and they do not validate a different compounded cream concentration. [3]

The other checked labels support their named local uses and describe exposure and safety precautions. Guidelines support low-dose local estrogen as a class for GSM, but class guidance and country approval are separate questions. US GSM guidance does not create an FDA-approved estriol product. Long-term safety evidence is less able to rule out uncommon harms than a brief symptom trial is to show relief. [1], [2], [3], [4], [5], [6], [7], [8]

Comparisons need matching formulations, populations and outcomes. An estriol user reporting better comfort than an estradiol user is not a head-to-head trial. Nor can lower receptor potency be converted into a milligram dose equivalence. The sensible question is whether the selected licensed regimen improves your target symptom with tolerable effects. [1], [2], [3], [4], [6]

What should be assessed before and during use?

The checked SmPCs retain contraindications for unexplained bleeding, known or suspected estrogen-sensitive cancer, untreated endometrial hyperplasia, relevant clotting or arterial disease, and significant liver disease. Ovesse adds specific pharmacy-selection restrictions, including certain vulvar conditions and previous unopposed systemic estrogen in someone with a uterus. Its narrow age and menopause criteria are not a general eligibility rule for every prescribed local product. [1], [2], [3], [4]

Local irritation, itching, breast discomfort or bleeding can occur. Report persistent or unexpected bleeding, new breast changes or symptoms that worsen instead of improving. Severe allergic swelling, breathing difficulty or symptoms suggestive of a clot or stroke require urgent assessment. Low-dose local guidance lowers concern about systemic exposure; it is not a promise that serious symptoms can be ignored. [1], [2], [3], [4]

Adding a compounded progesterone cream does not make an unverified systemic estriol regimen safe for the endometrium. Similarly, mixing estriol with estradiol in Biest changes the preparation and the evidence question. Approved product evidence should not be attached to a custom mixture simply because one ingredient is familiar. [8]

What should you review with the clinician or pharmacist?

Confirm that the symptoms fit GSM and that the chosen product is appropriate for your history. Record the exact formulation, initial-course dates, maintenance schedule, missed applications and symptoms. The ordinary menopause follow-up framework includes an initial review and ongoing reassessment; local symptoms, adverse effects and bleeding can justify earlier contact. Ovesse’s pharmacist pathway has its own selection rules and should not be bypassed with an internet checklist. [1], [6]

Routine serum estriol levels are not an established way to titrate ordinary local treatment. Routine endometrial ultrasound or biopsy is generally not required solely because low-dose local estrogen is used. These statements do not mean that bleeding, suspicious symptoms or a relevant history should go uninvestigated. Reassess a persistent problem rather than increasing frequency indefinitely or assuming every urinary symptom is tissue atrophy. [6], [7]

What happens when local estriol stops?

Vaginal symptoms can recur after local treatment ends because the underlying low-estrogen environment may persist. Continuing maintenance when beneficial is different from remaining indefinitely on the initial daily course. Discuss whether to continue, stop or restart, and use the named product’s restart instructions. Ovesse explicitly distinguishes restarting at maintenance when relief persists from repeating its initial course when bothersome symptoms return. [1], [6]

Do not treat recurrent symptoms as proof that the formulation has become addictive. Reassess the diagnosis, practical use and tolerability. If systemic HRT is also being stopped, decide separately what local treatment is still needed. New bleeding or a severe adverse reaction is a reason for clinical assessment, not simply an experiment with a lower frequency. [1], [2], [3], [4], [6]

How are the checked products stored?

Ovesse and the checked UK estriol cream say not to store above 25°C and not to freeze. Imvaggis says not above 25°C. Irish Ovestin says below 25°C and not to freeze. Keep the leaflet and follow the container and applicator instructions. Do not infer an identical storage rule for a compounded preparation: its pharmacy label and beyond-use date depend on that preparation. [1], [2], [3], [4], [8]

Keep medicine out of children’s reach and use local disposal advice. If a cream has frozen or a pessary has been exposed to heat, ask a pharmacist about that exact package. A foreign label’s shelf life does not establish the usable period of an opened or pharmacy-prepared product. [1], [2], [3], [4]

How does estriol compare with local estradiol?

Both can be used in named local formulations for vaginal symptoms, depending on country. Applicators, concentrations, initial courses and maintenance schedules differ. Comfort, ease of insertion, irritation, price and local availability can influence which product is practical, but amounts should not be converted by comparing the estrogen names alone. [1], [2], [3], [4], [6]

US patients can discuss FDA-approved local options rather than assume a compounded estriol preparation is necessary for “bioidentical” treatment. Estradiol itself can be supplied in regulated bioidentical medicines. Facial estriol, online hormone creams and mixed systemic products require separate evidence; none should be silently placed in this local vaginal comparison. [5], [8]

What questions appear in public discussions?

Archived public links ask what cream users should expect and whether estriol feels different from estradiol. The themes include local comfort, response timing and confusion between authorized vaginal medicine and online or compounded creams. The original threads could not be retrieved in this check, so these are archival leads rather than freshly verified quotations or a current sentiment survey. [9], [10]

No satisfaction score, participant identity or reported amount is used as evidence. The most useful response to a comparison story is to identify the actual product and symptom, then discuss benefit and irritation with the prescriber. A discussion about facial skin or systemic hot flashes does not confirm that the vaginal regimen treats those outcomes. [1], [2], [3], [4], [9], [10]

Common questions about estriol

Is estriol FDA-approved?

The FDA page checked here explicitly says there are no FDA-approved estriol-containing drugs. Overseas authorization and compounding are separate facts. [5] A regulated product in another country has its own route, indication and patient information. A US compound does not gain finished-product approval from that overseas authorization or from the ingredient’s natural origin. Ask which preparation is actually proposed and what source supports its use. See the product scope. [5]

Is all estriol cream the same strength?

No. The named 1 mg/g creams differ from other concentrations and mixtures. Match the package and marked applicator, not just the ingredient name. [1], [2], [4] Concentration, the marked applicator amount and the resulting estriol quantity must stay together. Similar packaging or an ingredient name cannot validate another device’s measurement. Mixtures can also contain other hormones, so ask the pharmacist to identify the complete prescription before comparing amounts or changing products. See application instructions. [1], [2], [4]

Can it treat my hot flashes?

These verified regimens concern local vaginal symptoms. They are not systemic hot-flash schedules. [1], [2], [3], [4] Local improvement and systemic replacement are different treatment goals. If hot flashes also need help, discuss a separate evidence-based option rather than increasing a vaginal amount beyond its instructions. The local product’s loading and maintenance schedule remains specific to that formulation and population. See benefits and scope. [1], [2], [3], [4]

Is a progestogen always needed?

The checked local-product SmPCs generally do not recommend one under their low-exposure schedules. That does not supply protection for a separate systemic estrogen or waive bleeding assessment. [1], [2], [3], [4] The answer depends on the actual local amount and schedule, not merely the word estriol. Keep any patch, tablet or other systemic treatment in the conversation. Unexplained bleeding still needs assessment, and a locally used estrogen should not be mistaken for a progestogen. See exposure and protection. [1], [2], [3], [4]

Can I use it after breast cancer?

That requires a personalized discussion of nonhormonal options, cancer treatment and the exact product’s contraindications, particularly during aromatase-inhibitor treatment. [1], [6], [7] General low-dose-local guidance and an individual product’s contraindications can differ. The discussion should consider persistent symptoms, previous treatment and recurrence uncertainty, with breast-cancer specialist involvement when relevant. Do not start a hormone or stop cancer treatment from a general guide alone. See risk assessment. [1], [6], [7]

Can I put vaginal estriol on my face?

The vaginal labels do not establish a facial indication, dose or long-term benefit. Do not transfer their evidence to that use. [1], [2], [3], [4] A vaginal leaflet describes the studied treatment of local symptoms, not every use of the same hormone. Changing the application site also changes the evidence question; absorption and benefit cannot be assumed from a vaginal amount. A cosmetic claim needs its own supporting evidence. See route and application. [1], [2], [3], [4]

Why do initial courses have different lengths?

Each full label defines its own formulation and schedule. Two, three and up to four weeks are different instructions, not an interchangeable “loading phase.” [1], [2], [3], [4] Use the actual product’s full initial course and maintenance instructions, with review when required. An apparent common ingredient does not let you borrow the shortest course or most convenient frequency. Ask about incomplete response, irritation or uncertainty before extending the initial phase yourself. See the named schedules. [1], [2], [3], [4]

Glossary

Definitions for interpreting the products, evidence and limits.

Estrogen

A hormone class that includes estradiol, estrone and estriol.

Bioidentical

Having the same molecular structure as a hormone made by the body; not a safety certification.

MHT / HRT

Menopausal hormone therapy; hormone replacement therapy is a broader term.

Vasomotor symptoms

Menopausal hot flashes and night sweats.

GSM

Genitourinary syndrome of menopause: symptoms and tissue changes involving genital and urinary areas.

Systemic treatment

Medicine delivered through the circulation to act throughout the body.

Local treatment

Treatment directed mainly at the tissue where it is applied; some absorption can still occur.

First-pass metabolism

Initial liver processing after a swallowed medicine is absorbed from the gut.

Endometrium

The lining inside the uterus.

Endometrial hyperplasia

Excess growth of uterine lining; some forms can precede cancer.

Progestogen

A medicine class including progesterone and synthetic progestins, used for uterine protection in systemic HRT.

Micronized progesterone

Progesterone processed into small particles to support absorption; route and schedule remain important.

Continuous combined

Estrogen and progestogen taken without planned monthly breaks.

Sequential

Progestogen taken during a defined part of an estrogen-treatment cycle.

Withdrawal bleed

A planned bleed associated with stopping the progestogen part of a sequential regimen.

Hysterectomy

Surgery to remove the uterus; it does not always remove the ovaries.

VTE

Venous thromboembolism: a clot in a vein, including leg clots and pulmonary embolism.

Pulmonary embolism

A clot blocking an artery in the lungs; a medical emergency.

Absolute risk

How often an event occurs in a specified population over a specified time.

Relative risk

An event rate in one group compared with another; it needs baseline risk to show practical size.

Compounded product

A pharmacy-prepared medicine; approval of an ingredient does not approve the finished preparation.

Contraindication

A circumstance in which a medicine should not be used according to its label.

Estriol / E3

An estrogen used in the named local vaginal products covered here.

Pessary

Here, a medicine placed in the vagina; distinct from a mechanical support device also called a pessary.

SmPC / RCP

Summary of Product Characteristics: the approved professional product information.

Excipient

An ingredient other than the active medicine; it can affect texture or local tolerability.

Maintenance regimen

The ongoing schedule after a product-specific initial course.

Aromatase inhibitor

A medicine that reduces estrogen production, used in some breast-cancer treatment.

How was this guide researched?

Full named labels define amounts, schedules, contraindications and storage. Regulators establish authorization; clinical guidelines inform follow-up without automatically expanding a product indication. Community evidence remains separate. The directory distinguishes full access, abstract-only access and unavailable archival links.

How this page was made

This Doserly editorial guide was prepared with AI assistance using public sources checked October 2, 2026. No independent clinician reviewer is claimed. Doserly develops a commercial tracking app. Original figures explain concepts and do not represent trial results. The directory identifies source revisions and access limitations. January 2027 is a review target; new evidence can require an earlier check.

Sources and updates

Related guides